Bioblast Pharma reports fourth quarter and year end 2016 financial results
Bioblast Pharma reported the net loss was ($3.1) million, or ($0.19) per basic and diluted share in the 2016 fourth quarter, versus a net loss of ($4.8) million, or ($0.34) per share, for the same 2015 period. Cash and equivalents as of De. 31, 2016 were $9.9 million. February 24, 2017